LQDA
Liquidia Corp
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Market Cap: 885 Million
Primary Exchange: NASDAQ
Website: http://liquidia.com/
Shares Outstanding: 64.9 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.31968096895241827
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2651 trading days
From: 2018-10-09 To: 2024-03-07
Lowest Point:
Liquidia Technologies: Targeting Pulmonary Arterial Hypertension Using Proprietary Drug Particle Generating Platform
via: SeekingAlpha at 2019-06-10 05:00:00:000
Ordinarily Avisol wouldn't be interested in a company like Liquidia ( LQDA ): our reasons - targeting a competitive 505((B))(2) pathway, facing competition from Big Pharma United Therapeutics ( UTHR ), which just recently closed an attractive deal with LQDA's major small pharma competitor Mann… read more...
Liquidia Technologies: Targeting Pulmonary Arterial Hypertension Using Proprietary Drug Particle Generating Platform
via: SeekingAlpha at 2019-06-10 05:00:00:000
Ordinarily Avisol wouldn't be interested in a company like Liquidia ( LQDA ): our reasons - targeting a competitive 505((B))(2) pathway, facing competition from Big Pharma United Therapeutics ( UTHR ), which just recently closed an attractive deal with LQDA's major small pharma competitor Mann… read more...
Liquidia Technologies: Targeting Pulmonary Arterial Hypertension Using Proprietary Drug Particle Generating Platform
via: SeekingAlpha at 2019-06-10 05:00:00:000
Ordinarily Avisol wouldn't be interested in a company like Liquidia ( LQDA ): our reasons - targeting a competitive 505((B))(2) pathway, facing competition from Big Pharma United Therapeutics ( UTHR ), which just recently closed an attractive deal with LQDA's major small pharma competitor Mann… read more...
Liquidia Technologies: Targeting Pulmonary Arterial Hypertension Using Proprietary Drug Particle Generating Platform
via: SeekingAlpha at 2019-06-10 05:00:00:000
Ordinarily Avisol wouldn't be interested in a company like Liquidia ( LQDA ): our reasons - targeting a competitive 505((B))(2) pathway, facing competition from Big Pharma United Therapeutics ( UTHR ), which just recently closed an attractive deal with LQDA's major small pharma competitor Mann… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|